Annovis Bio Inc (ANVS) Stock Price, Quote & News

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phas...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 875 3192

Website: www.annovisbio.com

Address:

101 Lindenwood Drive, Suite 225, Malvern, United States

LeftyT Feb. 3 at 4:21 PM

$ANVS I trimmed my position quite a bit and took profits above $4 back in December, but I'm starting to add back to my position on this dip below $3. Grabbed 800 more shares this morning at $2.685 ATM. Despite the mngt teams rookie errors, the potential of this drug is just too significant to ignore IMHO. Recruiting of the P3 trial is picking up now that 81 of the 82 trial sites are up and recruiting. Not sure what is holding up the Tampa site, but that doesn't matter much given all the other sites involved. https://clinicaltrials.gov/study/NCT06709014?term=buntanetap&rank=2#contacts-and-locations

2 · Reply

Rbrmd Feb. 2 at 6:26 PM

$ANVS

1 · Reply

Rbrmd Feb. 2 at 6:24 PM

$ANVS

0 · Reply

Veni_Vidi_Vici Feb. 2 at 11:09 AM

$ANVS https://www.google.com/search?q=annovis+bio&sca_esv=1cf3b1e2cbd119f3&rlz=1C1EJFA_enUS797US961&biw=1536&bih=729&aic=0&tbs=qdr%3Aw&sxsrf=ANbL-n7plWx4eC-obKCSV6tSaB8ArB9Tyg%3A1770030330083&ei=-oSAafboBJKg5NoPl-b40AI&gs_ssp=eJzj4tVP1zc0zKiMNy4uzjVUYDRgdGDw4k7My8svyyxWSMrMBwCUjwl1&oq=Annovis&gs_lp=Egxnd3Mtd2l6LXNlcnAiB0Fubm92aXMqAggAMhEQLhiABBiRAhjRAxjHARiKBTIFEAAYgAQyCxAAGIAEGJECGIoFMgUQABiABDIFEAAYgAQyCxAAGIAEGJECGIoFMgUQABiABDIFEAAYgAQyBRAAGIAEMgUQABiABDIgEC4YgAQYkQIY0QMYxwEYigUYlwUY3AQY3gQY4ATYAQFIqyJQAFinDXAAeAGQAQCYAeYBoAHICqoBBTAuNS4yuAEByAEA-AEBmAIIoALEH8ICEBAuGIAEGNEDGEMYxwEYigXCAgoQABiABBhDGIoFwgIREC4YgAQYsQMY0QMYgwEYxwHCAh8QLhiABBjRAxhDGMcBGIoFGJcFGNwEGN4EGOAE2AEBwgIOEC4YgAQYsQMYgwEYigXCAggQABiABBixA8ICCxAuGIAEGNEDGMcBwgILEC4YgAQYsQMYgwHCAgUQLhiABMICDhAuGIAEGLEDGNEDGMcBwgILEAAYgAQYsQMYgwHCAggQLhiABBixA8ICBxAAGIAEGArCAgwQLhiABBixAxgKGAuYAwC6BgYIARABGBSSBwkwLjQuMy44LTGgB6mDAbIHBTAuNC4zuAf-CsIHBzAuMS41LjLIBzGACAA&sclient=gws-wiz-serp#fpstate=ive&vld=cid:d6662590,vid:SrFqtppHqgY,st:0

0 · Reply

Madsj79 Feb. 2 at 10:16 AM

$ANVS The case for Annovis Bio is becoming increasingly tied to a shift in the broader scientific understanding of neurodegeneration. The articles from independent sources like SciTechDaily and ScienceAlert confirm that the most effective way to treat AD and PD is to intervene at the protein-seeding stage, protecting cellular energy before permanent damage occurs. This external validation aligns directly with Buntanetaps mechanism! While academic researchers describe this approach as the next frontier, Annovis is already in the final stages of clinical testing. Take in to context that a major institutional holder like Vanguard, seem convinced of the potential and added a sizeable portion of stock in Q4. They understand the huge potential in ANVS and have most likely heard of the exceptionally high patient retention rate of over 99% in the current AD phase 3 trial - compared to a normal drop out rate of 15-17%!!

0 · Reply

ReturnOfEsquire Feb. 1 at 10:07 PM

$ANVS https://scitechdaily.com/scientists-uncover-a-hidden-early-stage-of-alzheimers-that-they-can-stop/

1 · Reply

ReturnOfEsquire Feb. 1 at 10:05 PM

$ANVS https://indiandefencereview.com/scientists-gym-supplement-key-fighting-dementia/

0 · Reply

ReturnOfEsquire Feb. 1 at 8:31 PM

$ANVS https://www.sciencealert.com/missing-link-between-parkinsons-protein-and-damage-to-brain-cells-discovered

0 · Reply

ReturnOfEsquire Feb. 1 at 8:29 PM

$ANVS https://scitechdaily.com/this-simple-drug-combo-turns-thc-into-a-potential-alzheimers-therapy/

0 · Reply

Lando4 Jan. 30 at 7:23 PM

$ANVS Adding adding ✅

0 · Reply

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Dec 16, 2025, 8:00 AM EST - 7 weeks ago

Annovis to Host Corporate Update Webinar on January 28, 2026

Dec 3, 2025, 8:00 AM EST - 2 months ago

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Nov 24, 2025, 8:00 AM EST - 2 months ago

Annovis Announces Two Presentations at the CTAD 2025 Conference

Nov 18, 2025, 8:00 AM EST - 2 months ago

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

Nov 17, 2025, 1:07 PM EST - 2 months ago

Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients

Nov 17, 2025, 8:00 AM EST - 2 months ago

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Nov 12, 2025, 8:00 AM EST - 2 months ago

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 8:00 AM EST - 3 months ago

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

Oct 27, 2025, 8:00 AM EDT - 3 months ago

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Oct 15, 2025, 5:15 PM EDT - 3 months ago

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

Oct 10, 2025, 8:31 AM EDT - 4 months ago

Annovis Announces $6 Million Registered Direct Offering of Common Stock

Oct 9, 2025, 7:30 AM EDT - 4 months ago

Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

Sep 25, 2025, 7:30 AM EDT - 4 months ago

Annovis Appoints Mark Guerin as Chief Financial Officer

Sep 16, 2025, 7:30 AM EDT - 5 months ago

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Sep 2, 2025, 8:00 AM EDT - 5 months ago

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:05 PM EDT - 6 months ago

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:00 AM EDT - 6 months ago

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Jun 26, 2025, 8:00 AM EDT - 7 months ago

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Jun 19, 2025, 6:30 AM EDT - 8 months ago

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Jun 5, 2025, 8:00 AM EDT - 8 months ago

Annovis to Host Webinar and Live Q&A on June 24, 2025

May 13, 2025, 4:30 PM EDT - 9 months ago

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 8:00 AM EDT - 10 months ago

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Mar 27, 2025, 4:30 PM EDT - 11 months ago

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Mar 25, 2025, 8:00 AM EDT - 11 months ago

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Mar 21, 2025, 5:05 PM EDT - 11 months ago

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 11, 2025, 8:00 AM EDT - 11 months ago

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Feb 19, 2025, 8:30 AM EST - 1 year ago

Annovis to Host Patients' Live Forum on February 27, 2025

Feb 7, 2025, 8:00 AM EST - 1 year ago

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Feb 4, 2025, 4:31 PM EST - 1 year ago

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Feb 3, 2025, 6:22 AM EST - 1 year ago

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

Jan 31, 2025, 8:14 PM EST - 1 year ago

Annovis Bio, Inc. Announces Proposed Public Offering

Jan 14, 2025, 8:00 AM EST - 1 year ago

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

Dec 5, 2024, 8:30 AM EST - 1 year ago

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace

Dec 4, 2024, 2:21 PM EST - 1 year ago

/C O R R E C T I O N -- Today's Marketplace/

Nov 25, 2024, 8:00 AM EST - 1 year ago

Annovis to Host Year-End Investor Webcast on December 11, 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

Oct 15, 2024, 8:00 AM EDT - 1 year ago

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs

Oct 3, 2024, 8:30 AM EDT - 1 year ago

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

Jul 24, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

Jul 2, 2024, 4:13 PM EDT - 1 year ago

Annovis stock more than doubled on Tuesday: what happened?

Jul 2, 2024, 1:57 PM EDT - 1 year ago

Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial

Jun 26, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

Jun 11, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

May 21, 2024, 7:30 AM EDT - 1 year ago

Annovis Announces New Publication in a Peer-Reviewed Journal

LeftyT Feb. 3 at 4:21 PM

2 · Reply

Rbrmd Feb. 2 at 6:26 PM

$ANVS

1 · Reply

Rbrmd Feb. 2 at 6:24 PM

$ANVS

0 · Reply

Veni_Vidi_Vici Feb. 2 at 11:09 AM

0 · Reply

Madsj79 Feb. 2 at 10:16 AM

0 · Reply

ReturnOfEsquire Feb. 1 at 10:07 PM

$ANVS https://scitechdaily.com/scientists-uncover-a-hidden-early-stage-of-alzheimers-that-they-can-stop/

1 · Reply

ReturnOfEsquire Feb. 1 at 10:05 PM

$ANVS https://indiandefencereview.com/scientists-gym-supplement-key-fighting-dementia/

0 · Reply

ReturnOfEsquire Feb. 1 at 8:31 PM

$ANVS https://www.sciencealert.com/missing-link-between-parkinsons-protein-and-damage-to-brain-cells-discovered

0 · Reply

ReturnOfEsquire Feb. 1 at 8:29 PM

$ANVS https://scitechdaily.com/this-simple-drug-combo-turns-thc-into-a-potential-alzheimers-therapy/

0 · Reply

Lando4 Jan. 30 at 7:23 PM

$ANVS Adding adding ✅

0 · Reply

doyoujetset Jan. 30 at 5:19 PM

$ANVS Institutional Accumulation. Vanguard stepping up big🏦

2 · Reply

5DollarNana Jan. 30 at 5:18 PM

$ANVS booo.. should have broken even and sold. After almost 2 years of this I am pretty done…

2 · Reply

doyoujetset Jan. 30 at 5:18 PM

$ANVS Holding the 200 day MA⏳

0 · Reply

junkjar291 Jan. 30 at 3:51 PM

$ANVS At this rate by end of Feb this will be trading at new 52 weeks low. Why announce webinar 6weeks in advance and then present same information and keep crying about funding?

1 · Reply

ppl_first Jan. 30 at 2:51 PM

$ANVS 3 major yellow flags: Vague magnitude language Subgroup Emphasis CNS Space needs strong effects Not to mention, 40% enrolled instead of 100%. Watch for: first site closure. Bail immediately if that happens.

2 · Reply

EmotionlessRobot Jan. 30 at 11:53 AM

$ANVS Looks like the lack of major updates was priced in.

2 · Reply

Madsj79 Jan. 30 at 7:03 AM

$ANVS Meeting "in a month" was mentioned at the webinar. Market with no treatment at this point.

1 · Reply

kay91667 Jan. 30 at 12:52 AM

$ANVS how come the updated investor deck has no financial section at all? They should add it to show investors their plan to raise the funds to complete the phase 3. No way they can finish even 6 month trial with cash on hand now.

3 · Reply

philtheclown Jan. 29 at 8:58 PM

$ANVS paid bashing clowns working the crowd again😂hilarious

0 · Reply

junkjar291 Jan. 29 at 8:23 PM

$ANVS I wouldn't be surprised if they stop enrollment in coming month due to fund shortage, sites need payment for screening and on going data collection. No matter what hopium CEO smoking, they are in really bad situation. 19mil as of Dec 10, by now that might be down to 15mil, going-concern..

4 · Reply

LionNoRichy Jan. 29 at 7:54 PM

$ANVS should have sold at $5.5 😂 - cya all around the summer

0 · Reply

RockDoctor Jan. 29 at 5:00 PM

$ANVS $IOVA my two lotto tickets. gold/crypto/nasdaq are screaming mass liquidation event at any moment. won't be a good day for biotech...sigh

4 · Reply

Market Cap	71.56M
Revenue (ttm)	0.00
Net Income (ttm)	-24.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	250,800
Avg Vol	873,566
Day's Range	N/A - N/A
Shares Out	26.50M
Stochastic %K	8%
Beta	1.46
Analysts	Strong Sell
Price Target	$11.67